Zamestitel'naya terapiya pri pervichnykh immunodefitsitakh gumoral'nogo zvena
- 作者: Belan E.B1, Panina A.A1, Klyausov A.S1
-
隶属关系:
- 期: 编号 15 (2014)
- 页面: 40-44
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287384
- ID: 287384
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Immunoglobulins for intravenous administration are the main group of drugs for the replacement therapy of diseases accompanied by agammaglobulinemia. In each case, the choice of drug should be determined by clinical indications for its use, data on efficacy and safety, as well as individual patient’s tolerance.
全文:
参考
- van der Burg M., van Zelm M.C., Driessen G.J., et al. New frontiers of primary antibody deficiencies. Cell Mol. Life Sci. 2012; 69(1): 59-73.
- Driessen G., van der Burg M. Educational paper: primary antibody deficiencies. Eur. J. Pediatr. 2011; 170(6): 693-702.
- Blue Cross Blue Shield of Kansas City. Immune Globulin Therapy. An Independent Licensee of the Blue Crossand Blue Shield Association 2014. 33 p.
- Schroeder H.W., Dougherty C.J. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection. 2012; 40(6): 601-11
- Латышева Т.В. Внутривенные иммуноглобулины (ВВИГ, IVIG) в клинической практике. М., 2009. C. 3-39.
- Quinti I., Soresina A., Guerra A., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J. Clin lmmunol. 2011; 31(3): 315-22.
- Baris S., Ercan H., Cagan H.H., et al. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 2011; 21(7): 514-21.
- Orange J.S.1, Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006; 117(4): 525-53.
- Debes A., Bauer A., Kremer S. Переносимость и безопасность иммуноглобулина для внутривенного введения Октагам: проспективное наблюдательное исследование. Pharmacoepidemiol. Drug Saf. 2007; 16: 1038-47 (пер. на русский язык).
- Aghamohammadi A., Mohammadi J., Parvaneh N., et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int. Arch. Allergy Immunol. 2008; 147(2): 87-92.
- Ochs H.D., Pinciaro P.J. Octagam 5 %, an intravenous IgG product, is efficious and well tolerated in subjects with primary immunodeficiency diseases. J. Clin. Immunol. 2004; 24: 30914.
补充文件
